Shasha Jiang , Shilin Li , Song Liao , Jipeng Jiang , Ke Xu , Xia Tian , Qian Zheng , Jian Zhang , Jie Mei , Xinlian Wang , Jing Yuan , Yang Liu , Yongfu Ma
{"title":"ITGB1 是减少肺癌骨转移的治疗靶点","authors":"Shasha Jiang , Shilin Li , Song Liao , Jipeng Jiang , Ke Xu , Xia Tian , Qian Zheng , Jian Zhang , Jie Mei , Xinlian Wang , Jing Yuan , Yang Liu , Yongfu Ma","doi":"10.1016/j.nantod.2024.102338","DOIUrl":null,"url":null,"abstract":"<div><p>Bone metastasis of lung cancer often leads to severe clinical complications and high mortality rates. The current treatment methods mostly demonstrate limited efficacy due to their inadequate bone targeting capability and insufficient impact on the underlying mechanism of bone metastasis. From the bone metastasis in lung cancer patients, we find that integrin β1 (ITGB1) is a pivotal factor in the pathogenesis of lung cancer bone metastasis, influencing the proliferation, apoptosis, migration, and invasion of lung cancer cells. Therefore, we develop an ITGB1 short-interfering RNA (siRNA)-loaded cationic liposome to treat lung cancer bone metastasis and co-delivered zoledronic acid to enhance its bone-targeting efficacy (Z&S@CLs). The Z&S@CLs exhibit good capability in targeting bones, effectively suppressing the growth of existing bone metastasis tumors and delaying the occurrence of bone metastasis <em>in vivo</em>. Mechanistically, Z&S@CLs prevent the extravascular invasion of tumor cells by modulating the cellular cytoskeleton, inhibiting focal adhesion formation, and suppressing the PI3K/Akt signaling pathway. In summary, these findings provide a promising strategy based on ITGB1 for treating lung cancer bone metastasis.</p></div>","PeriodicalId":395,"journal":{"name":"Nano Today","volume":null,"pages":null},"PeriodicalIF":13.2000,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ITGB1 serves as a therapeutic target for reducing lung cancer bone metastasis\",\"authors\":\"Shasha Jiang , Shilin Li , Song Liao , Jipeng Jiang , Ke Xu , Xia Tian , Qian Zheng , Jian Zhang , Jie Mei , Xinlian Wang , Jing Yuan , Yang Liu , Yongfu Ma\",\"doi\":\"10.1016/j.nantod.2024.102338\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Bone metastasis of lung cancer often leads to severe clinical complications and high mortality rates. The current treatment methods mostly demonstrate limited efficacy due to their inadequate bone targeting capability and insufficient impact on the underlying mechanism of bone metastasis. From the bone metastasis in lung cancer patients, we find that integrin β1 (ITGB1) is a pivotal factor in the pathogenesis of lung cancer bone metastasis, influencing the proliferation, apoptosis, migration, and invasion of lung cancer cells. Therefore, we develop an ITGB1 short-interfering RNA (siRNA)-loaded cationic liposome to treat lung cancer bone metastasis and co-delivered zoledronic acid to enhance its bone-targeting efficacy (Z&S@CLs). The Z&S@CLs exhibit good capability in targeting bones, effectively suppressing the growth of existing bone metastasis tumors and delaying the occurrence of bone metastasis <em>in vivo</em>. Mechanistically, Z&S@CLs prevent the extravascular invasion of tumor cells by modulating the cellular cytoskeleton, inhibiting focal adhesion formation, and suppressing the PI3K/Akt signaling pathway. In summary, these findings provide a promising strategy based on ITGB1 for treating lung cancer bone metastasis.</p></div>\",\"PeriodicalId\":395,\"journal\":{\"name\":\"Nano Today\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":13.2000,\"publicationDate\":\"2024-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nano Today\",\"FirstCategoryId\":\"88\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1748013224001932\",\"RegionNum\":1,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Today","FirstCategoryId":"88","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1748013224001932","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
ITGB1 serves as a therapeutic target for reducing lung cancer bone metastasis
Bone metastasis of lung cancer often leads to severe clinical complications and high mortality rates. The current treatment methods mostly demonstrate limited efficacy due to their inadequate bone targeting capability and insufficient impact on the underlying mechanism of bone metastasis. From the bone metastasis in lung cancer patients, we find that integrin β1 (ITGB1) is a pivotal factor in the pathogenesis of lung cancer bone metastasis, influencing the proliferation, apoptosis, migration, and invasion of lung cancer cells. Therefore, we develop an ITGB1 short-interfering RNA (siRNA)-loaded cationic liposome to treat lung cancer bone metastasis and co-delivered zoledronic acid to enhance its bone-targeting efficacy (Z&S@CLs). The Z&S@CLs exhibit good capability in targeting bones, effectively suppressing the growth of existing bone metastasis tumors and delaying the occurrence of bone metastasis in vivo. Mechanistically, Z&S@CLs prevent the extravascular invasion of tumor cells by modulating the cellular cytoskeleton, inhibiting focal adhesion formation, and suppressing the PI3K/Akt signaling pathway. In summary, these findings provide a promising strategy based on ITGB1 for treating lung cancer bone metastasis.
期刊介绍:
Nano Today is a journal dedicated to publishing influential and innovative work in the field of nanoscience and technology. It covers a wide range of subject areas including biomaterials, materials chemistry, materials science, chemistry, bioengineering, biochemistry, genetics and molecular biology, engineering, and nanotechnology. The journal considers articles that inform readers about the latest research, breakthroughs, and topical issues in these fields. It provides comprehensive coverage through a mixture of peer-reviewed articles, research news, and information on key developments. Nano Today is abstracted and indexed in Science Citation Index, Ei Compendex, Embase, Scopus, and INSPEC.